Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Anthranilamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.56 |
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CFTR | P13569 | 1/20 | 0.54 |
| ▸ | IKBKB | O14920 | 1/20 | 0.53 |
| ▸ | METAP2 | P50579 | 1/20 | 0.52 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anthranilamide SCHEMBL29520647 | 1.00 | HSD17B10 (0.56) | HSD17B10ALDH1A1MAPTKDM4ETSHR | |
| Anthranilamide SCHEMBL27383812 | 1.00 | HSD17B10 (0.56) | HSD17B10ALDH1A1MAPTKDM4ETSHR | |
| Anthranilamide SCHEMBL29391044 | 0.97 | HSD17B10 (0.58) | HSD17B10ALDH1A1MAPTKDM4ETSHR | |
| Anthranilamide SCHEMBL7655669 | 0.97 | HSD17B10 (0.58) | HSD17B10ALDH1A1MAPTKDM4ETSHR | |
| Anthranilamide SCHEMBL38228 | 0.97 | HSD17B10 (0.58) | HSD17B10ALDH1A1MAPTKDM4ETSHR | |
| Anthranilamide SCHEMBL2801971 | 0.97 | HSD17B10 (0.58) | HSD17B10ALDH1A1MAPTKDM4ETSHR | |
| Anthranilamide SCHEMBL7650571 | 0.97 | HSD17B10 (0.58) | HSD17B10ALDH1A1MAPTKDM4ETSHR | |
| Anthranilamide SCHEMBL16415991 | 0.95 | HSD17B10 (0.56) | HSD17B10ALDH1A1MAPTKDM4ETSHR | |
| Anthranilamide SCHEMBL1643327 | 0.95 | HSD17B10 (0.56) | HSD17B10ALDH1A1MAPTKDM4ETSHR | |
| Anthranilamide SCHEMBL29105466 | 0.95 | HSD17B10 (0.56) | HSD17B10ALDH1A1MAPTKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173060-B2 | Oxime derivatives and their use as pharmaceutically active agents | HOFFMANN-LA ROCHE INC. | 2007-02-06 | — | — | US | claimed |
| CN-1771247-A | Oxime derivatives and their use as pharmaceutically active agents. | HOFFMANN LA ROCHE (CH) | 2006-05-10 | — | — | CN | claimed |
| EP-1613622-A1 | OXIME DERIVATIVES AND THEIR USE AS PHARMACEUTICALLY ACTIVE AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-11 | — | — | EP | claimed |
| US-20040214880-A1 | Oxime derivatives and their use as pharmaceutically active agents | HOFFMANN-LA ROCHE INC. | 2004-10-28 | — | — | US | claimed |
| WO-2004087693-A1 | OXIME DERIVATIVES AND THEIR USE AS PHARMACEUTICALLY ACTIVE AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-14 | — | — | WO | claimed |
| US-3931317-A | FUNGICIDE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-06 | — | — | US | claimed |
| CN-101304969-B | Benzene derivative or salt thereof | ASTELLAS PHARMA INC | 2012-01-18 | — | — | CN | disclosed |
| US-7662960-B2 | Beta-strand mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2010-02-16 | — | — | US | disclosed |
| EP-1797087-A4 | CARBO- AND HETERO-CYCLIC ANTIBIOTICS AND USE THEREOF | ULYSSES PHARMACEUTICAL PRODUCT (CA) | 2009-06-03 | — | — | EP | disclosed |
| EP-1646633-B1 | BETA-STRAND MIMETICS | CHOONGWAE PHARMA CORP (KR) | 2009-04-15 | — | — | EP | disclosed |
| CN-101304969-A | Benzene derivative or salt thereof | ASTELLAS PHARMA INC (JP) | 2008-11-12 | — | — | CN | disclosed |
| US-20080188499-A1 | Carbo- and Hetero-Cyclic Antibiotics and Use Thereof | ULYSSES PHARMACEUTICAL PRODUCTS INC. (CA) | 2008-08-07 | — | — | US | disclosed |
| CN-101027299-A | Carbon-and hetero-cyclic nitrofuran antibiotics and use thereof | ULYSSES PHARMACEUTICAL PRODUCT (CA) | 2007-08-29 | — | — | CN | disclosed |
| WO-1996036620-A1 | DIARYLDIAMINE DERIVATIVES AND THEIR USE AS DELTA OPIOID (ANT)-AGONISTS | SMITHKLINE BEECHAM S.P.A. (IT) | 1996-11-21 | — | — | WO | disclosed |
| US-4268510-A | DEMETHANIZATION, METABOLISM, RUMEN | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1981-05-19 | — | — | US | disclosed |
| EP-0010348-A1 | Heterocyclic trichloromethyl derivatives, process for their preparation and their use | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1980-04-30 | — | — | EP | disclosed |
| US-3974277-A | PESTICIDES | DIAMOND SHAMROCK CORPORATION (US) | 1976-08-10 | — | — | US | disclosed |
| US-3973021-A | 2-[2-(5-Nitro-2-furyl)vinyl]-4-(phydroxyanilino)quinazoline as a bactericide | DIAMOND SHAMROCK CORPORATION (US) | 1976-08-03 | — | — | US | disclosed |
| US-3970648-A | PESTICIDE, ANIMAL GROWTH REGULATOR | DIAMOND SHAMROCK CORPORATION (US) | 1976-07-20 | — | — | US | disclosed |
| US-3931317-A | FUNGICIDE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188499-A1 | Carbo- and Hetero-Cyclic Antibiotics and Use Thereof | SLC7A1, CYP2C19, ABCB11 | GAA 2021/4885PARP1 1461/4885HSD17B10 334/4885 |
| US-20040214880-A1 | Oxime derivatives and their use as pharmaceutically active agents | HDAC1, HDAC2, HDAC5 | GAA 88/4885PARP1 773/4885HSD17B10 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.